small-logo
ProfessionalsCapabilitiesInsights & NewsCareersLocations
About UsAlumniOpportunity & InclusionPro BonoCorporate Social Responsibility
Stay Connected:
facebookinstagramlinkedintwitteryoutube
Site Search
  • Professionals (320)
  • Capabilities (76)
  • Experience (54)
  • Insights & News (1,668)
  • Other Results (49)

Professionals 320 results

Sandra Edwards
Sandra Edwards
Partner
  • San Francisco
Email
+1 415-591-1412
vCard

Partner

  • San Francisco
Christopher Essig
Christopher Essig
Partner
  • Chicago
Email
+1 312-558-6229
vCard

Partner

  • Chicago
Terry Dee
Terry Dee
Partner
  • Chicago
Email
+1 312-558-8112
vCard

Partner

  • Chicago
View All Professionals

Capabilities 76 results

Practice Area

Financial Innovation & Regulation

Winston’s Financial Innovation & Regulation attorneys routinely counsel financial services, digital assets, and other clients on complex banking, crypto, FinTech, consumer financial, and securities matters. Many of our team members previously held positions as in-house counsel at global financial institutions and served in positions at government agencies, which gives us considerable experience in helping our clients obtain innovative, effective, and efficient solutions....Read more

Practice Area

Product Liability & Mass Torts

Major multinational companies trust Winston to defend their products and reputations in high-profile, high-stakes product liability and mass tort claims. Our Product Liability & Mass Torts Practice is one of the industry’s most seasoned, with a deep bench of experienced lawyers and a unique combination of extensive trial experience and expansive technical knowledge....Read more

Industry

Energy Industry Litigation & Investigations

With our reputation as a trial lawyers’ firm serving as our foundation, we advocate for a variety of power producers, oil and gas companies, and oilfield services providers in high-stakes litigation throughout U.S. district and appellate courts. We also handle sensitive investigations, contentious regulatory and enforcement issues, and arbitration. Our bench is stacked with innovative legal and commercial problem solvers, many of whom came to Winston from in-house positions, amplifying their appreciation for C-suite complexities. By combining our knowledge of the energy industry with first-rate trial skills, and the experience our practitioners have gained from learning our clients’ businesses, we are positioned to obtain the best result for our clients efficiently—whether in the courtroom or a negotiated solution....Read more

Experience 54 results

Experience

|

July 15, 2025

Winston Represented Cuadrilla Capital in the Acquisition of TigerGraph

Winston represented Cuadrilla Capital, a leading enterprise software investment firm, in the strategic investment of TigerGraph, an enterprise AI infrastructure and graph database leader. The investment will facilitate TigerGraph’s continued innovation and accelerate its business growth by positioning TigerGraph to expand its market-leading capabilities in fraud detection, entity resolution, customer 360 initiatives, supply chain management, and other mission-critical enterprise applications....Read more

Experience

|

May 27, 2025

PicoCELA Inc. Closes $1.8 Public Offering

Winston & Strawn represented Revere Securities LLC acted as the lead placement agent in connection with PicoCELA, Inc. in the closing of its public offering of 6,100,000 American Depositary Shares ("ADSs") at a public placement price of $0.30 per ADS. PicoCELA, Inc. received an aggregate gross proceeds of $1.83 million before deducting placement agent commission and other offering expenses. Each ADS represents one common share of the Company....Read more

Experience

|

April 23, 2025

Voyager Acquisition Corp. and VERAXA Biotech Announce Business Combination

Winston & Strawn represented Voyager Acquisition Corp. in its announced business combination agreement with VERAXA Biotech AG, a biopharmaceutical company developing next-generation antibody-based cancer therapies. The combination will result in VERAXA becoming a publicly traded company on Nasdaq under the ticker symbol “VERX”, with a pre-money equity valuation of $1.3 billion and up to $253 million in cash held in trust by Voyager. The transaction is expected to close in the fourth quarter of 2025, subject to regulatory and shareholder approvals....Read more
View All Experience

Insights & News 1,668 results

Recognitions

|

December 4, 2025

|

1 Min Read

Winston & Strawn Recognized in Chambers FinTech 2026 Guide

Chambers FinTech 2026 ranked Winston & Strawn as a leading law firm in FinTech Legal (USA), FinTech Legal: Blockchain & Cryptocurrencies (USA), and FinTech Legal: Corporate, Securities & Financing (USA).Additionally, four partners were ranked in four different practice areas....Read more

Tax Impacts

|

December 4, 2025

|

3 Min Read

Fair and Accountable IRS Reviews (FAIR) Act and Tax Court Improvement Act Passed by House of Representatives

On December 1, 2025, the U.S. House of Representatives passed two significant pieces of bipartisan legislation aimed at reforming tax administration and judicial review: the Fair and Accountable IRS Reviews (FAIR) Act (H.R. 5346) and the Tax Court Improvement Act (H.R. 5349).

The Reg E Reader

|

December 3, 2025

|

5 Min Read

The Status of The CFPB: A Year-End Review

The Reg E Reader features insights from Winston & Strawn’s multidisciplinary Consumer Financial Services Group on legal and enforcement developments related to Regulation E. The blog provides guidance and best practices for those who must remain compliant with the complex, evolving requirements of the regulation. In this blog post, Caitlin Mandel, Arman Aboutorabi, and Sydney Alexandra Rose provide a year-end review on the status of the CFPB, highlighting recent news, rulemaking activities, and hints toward the agency's future heading into 2026.

View All Insights & News

Other Results 49 results

Site Content

What Is the BPCIA?

Congress enacted the Biologics Price Competition and Innovation Act (BPCIA) to provide an abbreviated pathway for biosimilars to gain FDA approval through submission of an abbreviated Biologics License Application (aBLA)....Read more

Site Content

What Is General Causation?

In the product liability context, general causation is the legal and scientific determination of whether the product in question has the inherent capability to cause the alleged injury under certain circumstances. Establishment of general causation is a critical aspect of a plaintiff’s case, and typically requires scientific evidence, such as epidemiology or toxicology, and expert testimony to establish a causal connection between the product’s design, manufacturing, or warnings and the injury or injuries at issue. As contrasted to specific causation, the focus in a general causation inquiry is on whether the product or exposure, as a general matter, can cause the type of injury claimed by the plaintiff. A general causation inquiry does not assess any facts unique to a particular plaintiff....Read more

Law Glossary

What Is a Safe Harbor?

A safe harbor is a legal provision in a statute or regulation that provides protection from a legal liability or other penalty when certain conditions are met....Read more
Logo
facebookinstagramlinkedintwitteryoutube

Copyright © 2025. Winston & Strawn LLP

AlumniCorporate Transparency Act Task ForceDEI Compliance Task ForceEqual Rights AmendmentLaw GlossaryThe Oval UpdateWinston MinutePrivacy PolicyCookie PolicyFraud & Scam AlertsNoticesSubscribeAttorney Advertising